D. E. Ryono

Dual metalloprotease inhibitors: mercaptoacetyl-based fused heterocyclic dipeptide mimetics as inhibitors of angiotensin-converting enzyme and neutral endopeptidase.

N. Trippodo, H. Cheung, R. Misra, 1997, Journal of medicinal chemistry.

BMS‐180560, an insurmountable inhibitor of angiotensin II‐stimulated responses: comparison with losartan and EXP3174

M. Poss, S. Moreland, K. Dickinson, 1994, British journal of pharmacology.

Dual metalloprotease inhibitors. 6. Incorporation of bicyclic and substituted monocyclic azepinones as dipeptide surrogates in angiotensin-converting enzyme/neutral endopeptidase inhibitors.

N. Trippodo, J. Robl, T. Schaeffer, 1996, Journal of medicinal chemistry.

Vasopeptidase inhibitors: incorporation of geminal and spirocyclic substituted azepinones in mercaptoacyl dipeptides.

N. Trippodo, E. Sieber-McMaster, J. Robl, 1999, Journal of medicinal chemistry.

Aminodiol HIV protease inhibitors. Synthesis and structure-activity relationships of P1/P1' compounds: correlation between lipophilicity and cytotoxicity.

Ping Chen, S. Spergel, O. Kocy, 1996, Journal of medicinal chemistry.

Prodrugs of BMS-183920: metabolism and permeability considerations.

S. Chong, A. Marino, R. Morrison, 1996, Journal of pharmaceutical sciences.